A multicenter, prospective, observational study investigating the efficacy and safety of polatuzumab vedotin plus R-CHP therapy in patients with previously untreated diffuse large B-cell lymphoma (POLASTAR)
Latest Information Update: 18 Feb 2025
At a glance
- Drugs Polatuzumab vedotin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms POLASTAR
- Sponsors Chugai Pharmaceutical
Most Recent Events
- 18 Feb 2025 New trial record